Ioannou Maria, Papamichali Roidoula, Samara Maria, Paraskeva Efrosini, Papacharalambous Constantina, Baxevanidou Korina, Koukoulis George
Department of Pathology, University of Thessaly, Faculty of Medicine, Biopolis 41110, Larissa, Greece.
J BUON. 2016 May-Jun;21(3):618-25.
V600E is the most common activating BRAF mutation in colorectal carcinomas (CRCs). It is a crucial biomarker for patient selection and response to targeted therapy with BRAF V600E inhibitors. Previous studies using immunohistochemistry (IHC) have shown different results. In this study, we evaluated the IHC expression of the mutated BRAF protein in archival material from CRC specimens and correlated it with DNA sequence analysis.
51 cases of primary colon adenocarcinoma were stained with BRAF V600E-specific clone VE1 antibody against mutated BRAF protein. DNA sequence analysis was performed and the results were compared.
BRAF V600E protein was detected in the cytoplasm of neoplastic cells in 15 of the 51 examined cases (29.4%). The correlation between IHC staining and DNA sequence analysis showed 93.75% sensitivity and 100% specificity.
Our data show that IHC could be used in routine clinical practice as a screening method for BRAF V600E mutant protein detection in CRC patients.
V600E是结直肠癌（CRC）中最常见的BRAF激活突变。它是患者选择以及对BRAF V600E抑制剂靶向治疗反应的关键生物标志物。既往使用免疫组织化学（IHC）的研究显示了不同的结果。在本研究中，我们评估了CRC标本存档材料中突变BRAF蛋白的IHC表达，并将其与DNA序列分析相关联。
用针对突变BRAF蛋白的BRAF V600E特异性克隆VE1抗体对51例原发性结肠腺癌进行染色。进行DNA序列分析并比较结果。
在51例受检病例中的15例（29.4%）肿瘤细胞胞质中检测到BRAF V600E蛋白。IHC染色与DNA序列分析之间的相关性显示敏感性为93.75%，特异性为100%。
我们的数据表明，IHC可在常规临床实践中用作CRC患者BRAF V600E突变蛋白检测的筛查方法。
